Clinical success has been demonstrated with the β− emitters 90Y and 131I conjugated with anti-CD20 monoclonal antibodies in follicular B-cell non-Hodgkin lymphoma [6], 177Lu-labeled prostate-specific membrane antigen (PSMA) peptides in metastatic, castration-resistant prostate cancer (CRPC) and 177Lu-DOTATATE for neuroendocrine tumors [7,8]. This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.